Carfilzomib, Pomalidomide and Dexamethasone (KPd) in Patients with First Progression of Multiple Myeloma Refractory to Bortezomib and Lenalidomide. Final Report of the EMN011/HOVON114 Trial

Introduction and backgroundTreatment of newly diagnosed Multiple Myeloma (MM) with Bortezomib, Imid and Dexamethasone followed by high-dose therapy an…

Read the full article here

Related Articles